|1.||Wynn, Richard: 2 articles (01/2003 - 05/2002)|
|2.||Cromley, Debra A: 2 articles (01/2003 - 05/2002)|
|3.||He, Bokang: 2 articles (01/2003 - 05/2002)|
|4.||Kieras, Cathy J: 2 articles (01/2003 - 05/2002)|
|5.||Stern, Andrew M: 2 articles (01/2003 - 05/2002)|
|6.||Daly, Robert N: 2 articles (01/2003 - 05/2002)|
|7.||Seiffert, Dietmar: 2 articles (01/2003 - 05/2002)|
|8.||Hollis, Gregory F: 2 articles (01/2003 - 05/2002)|
|9.||Pedicord, Donna L: 2 articles (01/2003 - 05/2002)|
|10.||Billheimer, Jeffrey T: 2 articles (01/2003 - 05/2002)|
02/09/2009 - "However, higher AUC values of LN formulation as compared to CLB solution (p<0.01) in tumors suggested that the presence of DDAB on the lipid nanoparticles resulted in greater accumulation of the drug in tumors."
09/01/2014 - "Furthermore, the results of the in vitro biological studies allow the revisiting of the role of DDAB to the benefit of glioblastoma treatment, due to its efficacy in increasing the NLC uptake and reducing the viability of human glioblastoma cancer cells (U87MG). "
04/01/2007 - "Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE."
01/01/1998 - "The best therapeutic results, inhibition of tumor growth and prolonged survival time of treated vs. control mice, were obtained when plasmid expression vectors containing therapeutic genes were transferred into mice via DDAB/DOPE cationic liposome carrier on the third or fourth day following inoculation of mice with cancer cells. "
09/01/2002 - "In conclusion, a target-oriented Tf-DDAB liposome was made successfully and proved to be very efficient in DNA delivery into the cervical cancer cells in culture."
|2.||Glioblastoma (Glioblastoma Multiforme)
|3.||Breast Neoplasms (Breast Cancer)
01/01/2012 - "In this study, lipid/particle assemblies named LipoParticles (LNPs), consisting of a dimethyldidodecylammonium bromide (DMAB)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticle core surrounded by a 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) shell, were specially designed for anticancer drugs to bypass MDR in human breast cancer cells that overexpress P-gp. "
10/29/2015 - "Bivalent binding may be essential for a DDAb to cause thrombocytopenia. "
01/01/2003 - "The hypothesis that excluding patients based on positive DDAB reaction would reduce the frequency of thrombocytopenia was tested. "
05/15/2002 - "Two patients underwent conversion to a highly positive drug-dependent antibody (DDAB) status temporally associated with thrombocytopenia. "
05/15/2002 - "Screening patients for pre-existing or increasing DDAB titer during treatment with GP IIb/IIIa antagonists may reduce the incidence of drug-induced thrombocytopenia."
05/15/2002 - "Absorption of thrombocytopenia plasma with platelets reduced the DDAB ELISA signal, indicating that the test detects physiologically relevant antibodies. "
|3.||polylactic acid-polyglycolic acid copolymer (PLGA)
|4.||azelaic acid (Azelex)
|5.||cetrimonium (hexadecyltrimethylammonium bromide)
|7.||DNA (Deoxyribonucleic Acid)
|9.||3- (N- (N',N'- dimethylaminoethane)carbamoyl)cholesterol
|10.||Immunoglobulin G (IgG)
|1.||Transplantation (Transplant Recipients)